Wegovy (Semaglutide) Patent Expiration, LOE Window & CMS Spending
Wegovy (Semaglutide) by Novo Nordisk: FDA Orange Book core substance LOE 2031-12-05 (last listed 2041-02-17), 0 AB generics, $1.54B 2024 CMS Part D & Medicaid spend, and $1,349 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novo Nordisk |
| FDA Application & Pathway | N215256 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2031-12-05 |
| Last Listed Patent or Exclusivity Date | 2041-02-17 |
| Orange Book Patents (*PED Extensions) | 11 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $1.54B |
| 2024 Medicare Part D Spend | $301.3M |
| 2024 Medicaid Spend | $1.24B |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,349 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.